Contact

Resources

The latest in drug discovery, from novel targets and screening tools through to automation and computational chemistry

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Target Based Discovery

Post-Event Proceedings – Discovery Europe 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Discovery Europe 2023.
Read More
Target Based Discovery

Pivot Park Screening Centre: We Help You to Accelerate Drug Discovery

Are you looking for lead candidate compounds for your target or cellular phenotype, and do you want your drug discovery program to be more efficient, both in terms of time and cost?
Read More
Target Based Discovery

Navigating DEL Screening from Hit to Lead

The panel at Drug Discovery US discussed hit finding technologies, protein availability for screening, and hit-to-lead transition.
Read More
Target Based Discovery

Admescope: a Symeres Company

Your ADME-Tox Research Partner
Read More
Target Based Discovery

Tailor-made ADME-Tox

Admescope is a contract research organisation (CRO) providing the pharmaceutical industry with tailor-made ADME-Tox services to support the discovery and development of small molecules and biologics.
Read More
Target Based Discovery

Biotechne: Your Complete Protein Analysis Solution

Simple Western With Jess
Read More
Target Based Discovery

Biotechne: Your Complete Protein Analysis Solution

Protein analysis comes with many challenges—labor-intensive protocols increase time to result and multiple hands-on steps increase user error and data variability
Read More
Target Based Discovery

Biotechne: Service and Support Plans

Proteinsimple, a bio-techne brand, is here to support your research at every step of the way.
Read More
Target Based Discovery

Potential Antidote Discovered for Centuries-Old Toxic Mushroom

Researchers have discovered a potential antidote, indocyanine green (ICG), for the highly toxic death cap mushroom, Amanita phalloides.
Read More
Target Based Discovery

How DEL Screening is Used in Living Cells

Living cells create a more relevant physiological environment for DEL screening, says Dr Iolanda Micco, Associate Director of Chemistry & Alliances at Vipergen
Read More
Target Based Discovery

First Paediatric Patients Enrolled in Phase III Clinical Trial for Rare Genetic Disease

A clinical trial for the drug leniolisib will go ahead in studying paediatric patients with the rare genetic disease ADPS.
Read More
Target Based Discovery

Addressing Specific Targets and Dealing with Target Engagement

The panel discussion from Discovery US 2022, investigates into new technologies for target engagement and expanding the chemical space.
Read More
Target Based Discovery

University of Minnesota Awarded $6.5m for Male Contraceptive Discovery Effort

The grant could open the door to new oral contraceptive medication for men and prevent unwanted pregnancy.
Read More
Target Based Discovery

Accelerating Target Discovery with Genomic and CRISPR Techniques

Benedict Cross, Chief Technology Officer at PhoreMost, leads our Discussion Group on Target-Based Drug Discovery using Genomic and CRISPR techniques.
Read More
Target Based Discovery

Accelerating Target Deconvolution for Therapeutic Antibody Candidates

Target deconvolution is crucial to the phenotypic discovery process. Jenny Mattsson of BioInvent International explains how using CRISPR/Cas9 screening is a more efficient target deconvolution approach.
Read More
Target Based Discovery

Expanding the Druggable Toolbox: Improving Access to Undruggable Targets

In this Commentary article, we explore the innovative approaches towards drug target identification being championed by Cambridge-based biotechnology company PhoreMost. Identifying new druggable targets may help to address a range of unmet diseases.
Read More
Target Based Discovery

Protein Linked to Increased Lung Cancer Survival

Evidence shows that targeting TLR2 with an agonist reduces lung tumour growth in mouse models.
Read More
Target Based Discovery

Bundle Cultrex™ BME with Select Proteins & Save

Use Promo Code: PROTBME15 to receive 15% off your order
Read More
Target Based Discovery

Using Innovative Approaches to Expand the Druggable Genome

Investigating the mysteries of proteins considered undruggable to expand the druggable genome.
Read More
Target Based Discovery

In Vitro Potency Assays for Immune Cell-Mediated Killing with the Maestro Z

Cell-based therapies are a rapidly growing area of research with great promise.
Read More
Target Based Discovery

Target Identification, Phenotypic and Cell-based Screening

Oxford Global’s discussion group brings together specialists in target identification, phenotypic, and cell-based screening
Read More
Target Based Discovery

Validation of an Impedance-based Cytotoxicity Assay for High Throughput Screening

High throughput screening requires careful validation of assay performance
Read More
Target Based Discovery

Axion: Cardiac Activity Assay

In vitro models are a proven powerful strategy for studying disorders of the human heart.
Read More
Target Based Discovery

Axion: Teer With Maestro Z

High-throughput assessment of barrier function.
Read More
Target Based Discovery

Axion: Virology Studies

Simpler, faster assays for infectious diseases
Read More
Target Based Discovery

Axion MEA Plates

When your research requires insightful, high-quality data from microelectrode arrays (MEAs), Axion BioSystems’ MEA plates provide the right balance of throughput, electrode count, and ease of use for your experiments.
Read More
Target Based Discovery

Target Identification: Navigating the Intricate Environment of Human Biology

Balancing novelty and validity, the role of probability in target identification, and discussing the role of the genetic links to disease indications.
Read More
Target Based Discovery

Examining Target Identification and Validation in Drug Discovery

Target identification and validation forms the backbone of efforts to discover new drugs. Our expert panel discussed challenges and solutions in this field to drive safety and efficacy.
Read More
Target Based Discovery

Drugging KRAS: a Once ‘Undruggable’ Target

RAS mutations are the most common subfamily of oncogenes, so finding inhibitors could be extremely valuable to oncology research. However, they also make for particularly difficult targets. Andreas Mantoulidis explains how BI have been attempting to ‘drug the undruggable.’
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things discovery